 Spectrum --
January 2003
 In This Issue...
Toxicogenomics: the study of the genome-wide impact of chemicals
on humans and other organisms—promises to streamline, accelerate,
and reduce the cost of drug discovery and development. The goal
of toxicogenomics is to predict a drug candidate's toxicity using
the tools of genomics, proteomics, metabolomics, and other related
technologies. Widespread interest in the potential of toxicogenomics
has spawned a burgeoning industry. Related companies include tools
and service providers, many of which have developed toxicology-specific
DNA microarrays or databases, as well as drug developers that are
creating new toxicogenomics technology platforms. This report examines
the current state of the art of toxicogenomics, investigates its
potential applications, explores recent examples of its proof-of-principle
and development, and considers issues that may hinder its successful
implementation. We also identify leading companies in the field and describe their
related products and activities.
|
